Skip to main content
Top
Published in: Journal of Translational Medicine 1/2017

Open Access 01-12-2017 | Research

Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel

Authors: Ana Sílvia Pires-Luís, Pedro Costa-Pinheiro, Maria João Ferreira, Luís Antunes, Francisco Lobo, Jorge Oliveira, Rui Henrique, Carmen Jerónimo

Published in: Journal of Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

Promoter methylation has emerged as a promising class of epigenetic biomarkers for diagnosis and prognosis of renal cell tumors (RCTs). Although differential gene promoter methylation patterns have been reported for the major subtypes (clear cell, papillary and chromophobe renal cell carcinoma, and oncocytoma), validation of diagnostic performance in independent series have been seldom performed. Herein, we aimed at assessing the diagnostic performance of genes previously shown to be hypermethylated in RCTs in different clinical settings.

Methods

Promoter methylation levels of HOXA9 and OXR1 were assessed by quantitative methylation specific PCR. ROC curves were generated for OXR1, OXR1 combined with MST1R and HOXA9. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy were computed, maximizing specificity. Methylation levels were also correlated with clinical and pathological relevant parameters.

Results

HOXA9 and OXR1 promoter methylation was disclosed in 73 and 87% of RCTs, respectively. A two-gene methylation panel comprising OXR1 and MST1R identified malignancy with 98% sensitivity and 100% specificity, and clear cell renal cell carcinoma with 90% sensitivity and 98% specificity. HOXA9 promoter methylation allowed for discrimination between oncocytoma and both papillary and chromophobe renal cell carcinoma but only with 77% sensitivity and 73% specificity. Significantly higher OXR1 promoter methylation levels (p = 0.005) were associated with high nuclear grade in ccRCC.

Conclusions

A panel including OXR1 and MST1R promoter methylation allows specific and sensitive identification of renal cell tumors, and, especially, of clear cell renal cell carcinoma. Moreover, higher OXR1 promoter methylation levels associate with clear cell renal cell carcinoma nuclear grade, a surrogate for tumor aggressiveness. Thus, gene promoter methylation analysis might a useful ancillary tool in diagnostic management of renal masses.
Literature
1.
2.
go back to reference Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO classification of tumours of the urinary system and male genital organs. Lyon: IARC; 2016. Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO classification of tumours of the urinary system and male genital organs. Lyon: IARC; 2016.
3.
go back to reference Fernandez-Acenero MJ, Cazorla A, Manzarbeitia F. Immunohistochemistry for the differential diagnosis of renal tumors with oncocytic features. Urol Oncol. 2011;29:545–9.CrossRefPubMed Fernandez-Acenero MJ, Cazorla A, Manzarbeitia F. Immunohistochemistry for the differential diagnosis of renal tumors with oncocytic features. Urol Oncol. 2011;29:545–9.CrossRefPubMed
4.
go back to reference Tsivian M, Rampersaud EN Jr, del Pilar Laguna Pes M, Joniau S, Leveillee RJ, Shingleton WB, Aron M, Kim CY, DeMarzo AM, Desai MM. Small renal mass biopsy—how, what and when: report from an international consensus panel. BJU Int. 2014;113:854–63.CrossRefPubMed Tsivian M, Rampersaud EN Jr, del Pilar Laguna Pes M, Joniau S, Leveillee RJ, Shingleton WB, Aron M, Kim CY, DeMarzo AM, Desai MM. Small renal mass biopsy—how, what and when: report from an international consensus panel. BJU Int. 2014;113:854–63.CrossRefPubMed
5.
go back to reference Al-Ahmadie HA, Alden D, Fine SW, Gopalan A, Touijer KA, Russo P, Reuter VE, Tickoo SK. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol. 2011;35:949–61.CrossRefPubMed Al-Ahmadie HA, Alden D, Fine SW, Gopalan A, Touijer KA, Russo P, Reuter VE, Tickoo SK. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol. 2011;35:949–61.CrossRefPubMed
6.
go back to reference Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17:487–500.CrossRefPubMed Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17:487–500.CrossRefPubMed
7.
go back to reference Jeronimo C, Henrique R. Epigenetic biomarkers in urological tumors: a systematic review. Cancer Lett. 2014;342:264–74.CrossRefPubMed Jeronimo C, Henrique R. Epigenetic biomarkers in urological tumors: a systematic review. Cancer Lett. 2014;342:264–74.CrossRefPubMed
9.
go back to reference la Rosa AH, Acker M, Swain S, Manoharan M. The role of epigenetics in kidney malignancies. Cent Eur J Urol. 2015;68:157–64. la Rosa AH, Acker M, Swain S, Manoharan M. The role of epigenetics in kidney malignancies. Cent Eur J Urol. 2015;68:157–64.
10.
go back to reference Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K, Verma A. Role of DNA methylation in renal cell carcinoma. J Hematol Oncol. 2015;8:88.CrossRefPubMedPubMedCentral Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K, Verma A. Role of DNA methylation in renal cell carcinoma. J Hematol Oncol. 2015;8:88.CrossRefPubMedPubMedCentral
11.
go back to reference Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, Schostak M, Schrader M. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer. 2006;95:1701–7.CrossRefPubMedPubMedCentral Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, Schostak M, Schrader M. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer. 2006;95:1701–7.CrossRefPubMedPubMedCentral
12.
go back to reference Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Kollermann J, Miller K, Schrader M. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res. 2006;12:5040–6.CrossRefPubMed Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Kollermann J, Miller K, Schrader M. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res. 2006;12:5040–6.CrossRefPubMed
13.
go back to reference Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, Teixeira MR, Jeronimo C. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer. 2007;7:133.CrossRefPubMedPubMedCentral Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, Teixeira MR, Jeronimo C. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer. 2007;7:133.CrossRefPubMedPubMedCentral
14.
go back to reference Pires-Luís AS, Lobo F, Vieira-Coimbra M, Costa-Pinheiro P, Antunes L, Oliveira J, Henrique R, Jerónimo C. MST1R methylation as a diagnostic biomarker in renal cell tumors. Acta Urol Port. 2015;32:64–70. Pires-Luís AS, Lobo F, Vieira-Coimbra M, Costa-Pinheiro P, Antunes L, Oliveira J, Henrique R, Jerónimo C. MST1R methylation as a diagnostic biomarker in renal cell tumors. Acta Urol Port. 2015;32:64–70.
15.
go back to reference Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 2005;65:4598–606.CrossRefPubMed Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 2005;65:4598–606.CrossRefPubMed
16.
go back to reference de Caceres II, Dulaimi E, Hoffman AF, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res. 2006;66:5021–8.CrossRef de Caceres II, Dulaimi E, Hoffman AF, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res. 2006;66:5021–8.CrossRef
17.
go back to reference Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Itesako T, Kawamoto K, et al. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol. 2008;180:343–51.CrossRefPubMed Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Itesako T, Kawamoto K, et al. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol. 2008;180:343–51.CrossRefPubMed
18.
go back to reference Morris MR, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Teh BT, Latif F, Maher ER. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer. 2008;98:496–501.CrossRefPubMedPubMedCentral Morris MR, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Teh BT, Latif F, Maher ER. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer. 2008;98:496–501.CrossRefPubMedPubMedCentral
19.
go back to reference McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, Clarke NW, Brown MD, Kishida T, Yao M, et al. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer. 2009;8:31.CrossRefPubMedPubMedCentral McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, Clarke NW, Brown MD, Kishida T, Yao M, et al. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer. 2009;8:31.CrossRefPubMedPubMedCentral
20.
go back to reference Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F, Maher ER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010;29:2104–17.CrossRefPubMedPubMedCentral Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F, Maher ER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010;29:2104–17.CrossRefPubMedPubMedCentral
21.
go back to reference Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene. 2011;30:1390–401.CrossRefPubMed Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene. 2011;30:1390–401.CrossRefPubMed
22.
go back to reference Ibragimova I, Slifker MJ, Maradeo ME, Banumathy G, Dulaimi E, Uzzo RG, Cairns P. Genome-wide promoter methylome of small renal masses. PLoS ONE. 2013;8:e77309.CrossRefPubMedPubMedCentral Ibragimova I, Slifker MJ, Maradeo ME, Banumathy G, Dulaimi E, Uzzo RG, Cairns P. Genome-wide promoter methylome of small renal masses. PLoS ONE. 2013;8:e77309.CrossRefPubMedPubMedCentral
23.
go back to reference Slater AA, Alokail M, Gentle D, Yao M, Kovacs G, Maher ER, Latif F. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma. Epigenetics. 2013;8:252–67.CrossRefPubMedPubMedCentral Slater AA, Alokail M, Gentle D, Yao M, Kovacs G, Maher ER, Latif F. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma. Epigenetics. 2013;8:252–67.CrossRefPubMedPubMedCentral
24.
go back to reference Patricio P, Ramalho-Carvalho J, Costa-Pinheiro P, Almeida M, Barros-Silva JD, Vieira J, Dias PC, Lobo F, Oliveira J, Teixeira MR, et al. Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis. J Cell Mol Med. 2013;17:1048–58.CrossRefPubMedPubMedCentral Patricio P, Ramalho-Carvalho J, Costa-Pinheiro P, Almeida M, Barros-Silva JD, Vieira J, Dias PC, Lobo F, Oliveira J, Teixeira MR, et al. Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis. J Cell Mol Med. 2013;17:1048–58.CrossRefPubMedPubMedCentral
25.
go back to reference Pires-Luis AS, Vieira-Coimbra M, Ferreira MJ, Ramalho-Carvalho J, Costa-Pinheiro P, Antunes L, Dias PC, Lobo F, Oliveira J, Graca I, et al. Prognostic significance of MST1R dysregulation in renal cell tumors. Am J Cancer Res. 2016;6:1799–811.PubMedPubMedCentral Pires-Luis AS, Vieira-Coimbra M, Ferreira MJ, Ramalho-Carvalho J, Costa-Pinheiro P, Antunes L, Dias PC, Lobo F, Oliveira J, Graca I, et al. Prognostic significance of MST1R dysregulation in renal cell tumors. Am J Cancer Res. 2016;6:1799–811.PubMedPubMedCentral
26.
go back to reference Leao RR, Richard PO, Jewett MA. Indications for biopsy and the current status of focal therapy for renal tumours. Transl Androl Urol. 2015;4:283–93.PubMedPubMedCentral Leao RR, Richard PO, Jewett MA. Indications for biopsy and the current status of focal therapy for renal tumours. Transl Androl Urol. 2015;4:283–93.PubMedPubMedCentral
28.
go back to reference Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol. 2009;40:10–29.CrossRefPubMed Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol. 2009;40:10–29.CrossRefPubMed
29.
go back to reference Costa VL, Henrique R, Danielsen SA, Eknaes M, Patricio P, Morais A, Oliveira J, Lothe RA, Teixeira MR, Lind GE, Jeronimo C. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics. 2011;6:1120–30.CrossRefPubMed Costa VL, Henrique R, Danielsen SA, Eknaes M, Patricio P, Morais A, Oliveira J, Lothe RA, Teixeira MR, Lind GE, Jeronimo C. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics. 2011;6:1120–30.CrossRefPubMed
30.
go back to reference Ellinger J, Holl D, Nuhn P, Kahl P, Haseke N, Staehler M, Siegert S, Hauser S, Stief CG, Muller SC, Bastian PJ. DNA hypermethylation in papillary renal cell carcinoma. BJU Int. 2011;107:664–9.CrossRefPubMed Ellinger J, Holl D, Nuhn P, Kahl P, Haseke N, Staehler M, Siegert S, Hauser S, Stief CG, Muller SC, Bastian PJ. DNA hypermethylation in papillary renal cell carcinoma. BJU Int. 2011;107:664–9.CrossRefPubMed
31.
go back to reference Chopra S, Liu J, Alemozaffar M, Nichols PW, Aron M, Weisenberger DJ, Collings CK, Syan S, Hu B, Desai M, et al. Improving needle biopsy accuracy in small renal mass using tumor-specific DNA methylation markers. Oncotarget. 2017;8:5439–48.PubMed Chopra S, Liu J, Alemozaffar M, Nichols PW, Aron M, Weisenberger DJ, Collings CK, Syan S, Hu B, Desai M, et al. Improving needle biopsy accuracy in small renal mass using tumor-specific DNA methylation markers. Oncotarget. 2017;8:5439–48.PubMed
32.
go back to reference Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, Califano JA, Sidransky D. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64:5511–7.CrossRefPubMed Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, Califano JA, Sidransky D. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64:5511–7.CrossRefPubMed
33.
go back to reference Battagli C, Uzzo RG, Dulaimi E, de Caceres II, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 2003;63:8695–9.PubMed Battagli C, Uzzo RG, Dulaimi E, de Caceres II, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 2003;63:8695–9.PubMed
34.
go back to reference Silva-Santos RM, Costa-Pinheiro P, Luis A, Antunes L, Lobo F, Oliveira J, Henrique R, Jeronimo C. MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer. 2013;109:2646–53.CrossRefPubMedPubMedCentral Silva-Santos RM, Costa-Pinheiro P, Luis A, Antunes L, Lobo F, Oliveira J, Henrique R, Jeronimo C. MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer. 2013;109:2646–53.CrossRefPubMedPubMedCentral
35.
go back to reference Richard PO, Jewett MA, Tanguay S, Saarela O, Liu ZA, Pouliot F, Kapoor A, Rendon R, Finelli A. Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. BJU Int. 2017;119:543–9.CrossRefPubMed Richard PO, Jewett MA, Tanguay S, Saarela O, Liu ZA, Pouliot F, Kapoor A, Rendon R, Finelli A. Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. BJU Int. 2017;119:543–9.CrossRefPubMed
Metadata
Title
Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel
Authors
Ana Sílvia Pires-Luís
Pedro Costa-Pinheiro
Maria João Ferreira
Luís Antunes
Francisco Lobo
Jorge Oliveira
Rui Henrique
Carmen Jerónimo
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2017
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-017-1248-y

Other articles of this Issue 1/2017

Journal of Translational Medicine 1/2017 Go to the issue